Literature DB >> 27676320

Headache Disorders May Be a Risk Factor for the Development of New Onset Hypothyroidism.

Andrew T Martin1, Susan M Pinney1, Changchun Xie1, Robert L Herrick1, Yun Bai1, Jeanette Buckholz1, Vincent T Martin2.   

Abstract

OBJECTIVE: To determine whether headache disorders are a risk factor for the development of new onset hypothyroidism.
BACKGROUND: Past studies have reported associations between headache disorders and hypothyroidism, but the directionality of the association is unknown.
METHODS: This was a longitudinal retrospective cohort study using data from the Fernald Medical Monitoring Program (FMMP). Residents received physical examinations and thyroid function testing every 3 years during the 20 year program. Residents were excluded from the cohort if there was evidence of past thyroid disease or abnormal thyroid function tests at the first office visit. A diagnosis of a headache disorder was established by self-report of "frequent headaches," use of any headache-specific medication, or a physician diagnosis of a headache disorder. The primary outcome measure was new onset hypothyroidism defined as the initiation of thyroid replacement therapy or TSH ≥ 10 without thyroid medication. A Cox survival analysis with time dependent variables were used for the model. Headache disorders, age, sex, body mass index, income, smoking, narcotic use, and hypothyroidism-producing medications were independent variables in the model.
RESULTS: Data from 8412 residents enrolled in the FMMP were used in the current study. Headache disorders were present in about 26% of the residents and new onset hypothyroidism developed in ∼7%. The hazard ratio for the development of new onset hypothyroidism was 1.21 (95% CI = 1.001, 1.462) for those with headache disorders.
CONCLUSIONS: Headache disorders may be associated with an increased risk for the development of new onset hypothyroidism.
© 2016 American Headache Society.

Entities:  

Keywords:  headache; hypothyroidism; migraine

Mesh:

Year:  2016        PMID: 27676320      PMCID: PMC8805018          DOI: 10.1111/head.12943

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  39 in total

Review 1.  Smoking and thyroid.

Authors:  Wilmar M Wiersinga
Journal:  Clin Endocrinol (Oxf)       Date:  2013-05-11       Impact factor: 3.478

2.  Medication patterns of recurrent headache sufferers: a community study.

Authors:  S P Forward; P J McGrath; D MacKinnon; T L Brown; J Swann; E L Currie
Journal:  Cephalalgia       Date:  1998-04       Impact factor: 6.292

3.  T-cell subsets and expression of integrins in peripheral blood of patients with migraine.

Authors:  M Empl; P Sostak; M Breckner; M Riedel; N Müller; R Gruber; S Förderreuther; A Straube
Journal:  Cephalalgia       Date:  1999-10       Impact factor: 6.292

Review 4.  The cost of migraine and its treatment.

Authors:  Lawrence D Goldberg
Journal:  Am J Manag Care       Date:  2005-06       Impact factor: 2.229

5.  Comparison of endocrine-mediated effects of two bisphenol A related compounds, 2,2-bis(4-cyanatophyenyl)propane and 4,4'-cyclohexylidenebisphenol, based on subacute oral toxicity studies using rats.

Authors:  Kanji Yamasaki; Hirokazu Okuda
Journal:  Toxicol Lett       Date:  2011-11-07       Impact factor: 4.372

6.  Serum dopamine-beta-hydroxylase activity in migraine.

Authors:  F Gotoh; T Kanda; F Sakai; M Yamamoto; T Takeoka
Journal:  Arch Neurol       Date:  1976-09

Review 7.  The effects of opioids and opioid analogs on animal and human endocrine systems.

Authors:  Cassidy Vuong; Stan H M Van Uum; Laura E O'Dell; Kabirullah Lutfy; Theodore C Friedman
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

8.  Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study.

Authors:  Stewart J Tepper; Carl G H Dahlöf; Andrew Dowson; Lawrence Newman; Hank Mansbach; Martin Jones; Ba Pham; Chris Webster; Reijo Salonen
Journal:  Headache       Date:  2004-10       Impact factor: 5.887

Review 9.  Thyroid-adrenergic interactions: physiological and clinical implications.

Authors:  J Enrique Silva; Suzy D C Bianco
Journal:  Thyroid       Date:  2008-02       Impact factor: 6.568

10.  Headache in hypothyroidism. Prevalence and outcome under thyroid hormone therapy.

Authors:  T Moreau; E Manceau; F Giroud-Baleydier; R Dumas; M Giroud
Journal:  Cephalalgia       Date:  1998-12       Impact factor: 6.292

View more
  6 in total

1.  Common variants at 5q33.1 predispose to migraine in African-American children.

Authors:  Xiao Chang; Renata Pellegrino; James Garifallou; Michael March; James Snyder; Frank Mentch; Jin Li; Cuiping Hou; Yichuan Liu; Patrick M A Sleiman; Hakon Hakonarson
Journal:  J Med Genet       Date:  2018-09-28       Impact factor: 6.318

Review 2.  Migrainomics - identifying brain and genetic markers of migraine.

Authors:  Dale R Nyholt; David Borsook; Lyn R Griffiths
Journal:  Nat Rev Neurol       Date:  2017-11-17       Impact factor: 42.937

3.  Headache: Headache disorders may be a harbinger of hypothyroidism.

Authors:  Heather Wood
Journal:  Nat Rev Neurol       Date:  2016-10-07       Impact factor: 42.937

Review 4.  Is Migraine Primarily a Metaboloendocrine Disorder?

Authors:  Innocenzo Rainero; Flora Govone; Annalisa Gai; Alessandro Vacca; Elisa Rubino
Journal:  Curr Pain Headache Rep       Date:  2018-04-04

Review 5.  Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.

Authors:  Leonardo Biscetti; Gioacchino De Vanna; Elena Cresta; Ilenia Corbelli; Lorenzo Gaetani; Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  J Neuroinflammation       Date:  2021-11-08       Impact factor: 8.322

6.  High rates of (treated) hypothyroidism among chronic migraine patients consulting a specialized headache clinic: are we missing something?

Authors:  Marcelo Filipchuk; Jesica Gassmann; Tatiana Castro Zamparella; Maria Cecilia Tibaldo; Mariela Carpinella; Pablo Sesto Tagliavini; Pablo Scarnato; Maria Teresa Goicochea; Osvaldo Bruera; Diego Martin Conci Magris; Marco Lisicki
Journal:  Neurol Sci       Date:  2021-07-20       Impact factor: 3.830

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.